ZA200205142B - Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune and respiratory diseases. - Google Patents

Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune and respiratory diseases. Download PDF

Info

Publication number: ZA200205142B
Authority: ZA; South Africa
Prior art keywords: methyl; propionic acid; acetyl; phenyl; ureido
Prior art date: 1999-12-28

Application number

ZA200205142A

Other languages

English (en)

Inventor

Chupak Louis Stanley

Duplantier Allen Jacob

Lau Wan Fang

Milici Anthony John

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-28

Filing date

2002-06-26

Publication date

2003-09-29

2002-06-26 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-09-29 Publication of ZA200205142B publication Critical patent/ZA200205142B/en

Links

230000002757 inflammatory effect Effects 0.000 title claims description 7
208000023275 Autoimmune disease Diseases 0.000 title claims description 6
208000027866 inflammatory disease Diseases 0.000 title claims description 6
230000001363 autoimmune Effects 0.000 title claims description 5
208000023504 respiratory system disease Diseases 0.000 title claims description 5
239000003112 inhibitor Substances 0.000 title description 51
230000027455 binding Effects 0.000 title description 12
230000001419 dependent effect Effects 0.000 title description 12
150000001875 compounds Chemical class 0.000 claims description 136
-1 (C2-Cs) -alkynyl Chemical group 0.000 claims description 68
108010008212 Integrin alpha4beta1 Proteins 0.000 claims description 58
125000000623 heterocyclic group Chemical group 0.000 claims description 33
230000002401 inhibitory effect Effects 0.000 claims description 27
125000000753 cycloalkyl group Chemical group 0.000 claims description 24
125000003118 aryl group Chemical group 0.000 claims description 23
125000000217 alkyl group Chemical group 0.000 claims description 21
125000001072 heteroaryl group Chemical group 0.000 claims description 21
230000021164 cell adhesion Effects 0.000 claims description 17
230000001404 mediated effect Effects 0.000 claims description 15
229910052799 carbon Inorganic materials 0.000 claims description 12
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 9
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
125000003342 alkenyl group Chemical group 0.000 claims description 7
125000003545 alkoxy group Chemical group 0.000 claims description 7
239000004202 carbamide Substances 0.000 claims description 7
238000000034 method Methods 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
125000004076 pyridyl group Chemical group 0.000 claims description 6
125000000304 alkynyl group Chemical group 0.000 claims description 5
230000008569 process Effects 0.000 claims description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
125000002541 furyl group Chemical group 0.000 claims description 4
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 4
230000003110 anti-inflammatory effect Effects 0.000 claims description 3
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
230000001717 pathogenic effect Effects 0.000 claims description 3
125000001544 thienyl group Chemical group 0.000 claims description 3
201000001320 Atherosclerosis Diseases 0.000 claims description 2
241000124008 Mammalia Species 0.000 claims description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 2
208000006673 asthma Diseases 0.000 claims description 2
201000010099 disease Diseases 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
229910052757 nitrogen Inorganic materials 0.000 claims description 2
125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
125000000168 pyrrolyl group Chemical group 0.000 claims description 2
206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 395
235000019260 propionic acid Nutrition 0.000 claims 46
239000001257 hydrogen Substances 0.000 claims 18
229910052739 hydrogen Inorganic materials 0.000 claims 18
239000002253 acid Substances 0.000 claims 14
150000002431 hydrogen Chemical class 0.000 claims 9
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims 4
229940124597 therapeutic agent Drugs 0.000 claims 4
125000004093 cyano group Chemical group *C#N 0.000 claims 3
125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
229910014585 C2-Ce Inorganic materials 0.000 claims 2
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 2
239000005977 Ethylene Substances 0.000 claims 2
LUBJCRLGQSPQNN-UHFFFAOYSA-N Z-phenylurea Natural products NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 claims 2
125000002877 alkyl aryl group Chemical group 0.000 claims 2
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
125000005605 benzo group Chemical group 0.000 claims 2
125000000000 cycloalkoxy group Chemical group 0.000 claims 2
229910052736 halogen Inorganic materials 0.000 claims 2
150000002367 halogens Chemical class 0.000 claims 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
125000002883 imidazolyl group Chemical group 0.000 claims 2
125000000842 isoxazolyl group Chemical group 0.000 claims 2
125000002757 morpholinyl group Chemical group 0.000 claims 2
125000002971 oxazolyl group Chemical group 0.000 claims 2
125000003386 piperidinyl group Chemical group 0.000 claims 2
125000000714 pyrimidinyl group Chemical group 0.000 claims 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 2
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 2
125000000335 thiazolyl group Chemical group 0.000 claims 2
FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 claims 1
125000005955 1H-indazolyl group Chemical group 0.000 claims 1
GNNPQRIXVXCPCJ-UHFFFAOYSA-N 2,2-difluoro-3-[3-[1-[methyl-[2-[6-[(2-methylphenyl)carbamoylamino]pyridin-3-yl]acetyl]amino]ethyl]pyrazol-1-yl]propanoic acid Chemical compound C1=CN(CC(F)(F)C(O)=O)N=C1C(C)N(C)C(=O)CC(C=N1)=CC=C1NC(=O)NC1=CC=CC=C1C GNNPQRIXVXCPCJ-UHFFFAOYSA-N 0.000 claims 1
MJOBSGCJLJBOFA-UHFFFAOYSA-N 2-(benzenesulfonamido)-3-[4-[1-[2-[4-(phenoxymethyl)phenyl]acetyl]pyrrolidin-2-yl]imidazol-1-yl]propanoic acid Chemical compound C=1C=CC=CC=1S(=O)(=O)NC(C(=O)O)CN(C=1)C=NC=1C1CCCN1C(=O)CC(C=C1)=CC=C1COC1=CC=CC=C1 MJOBSGCJLJBOFA-UHFFFAOYSA-N 0.000 claims 1
UUMAQMJGBGZBKP-UHFFFAOYSA-N 2-(methanesulfonamido)-3-[5-[1-[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]thiophen-3-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)NC(CC(C)C)C1=CC(CC(NS(C)(=O)=O)C(O)=O)=CS1 UUMAQMJGBGZBKP-UHFFFAOYSA-N 0.000 claims 1
JKSDTYRGSMOXQG-UHFFFAOYSA-N 2-[(2,6-dichlorobenzoyl)amino]-3-[3-[[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-methylamino]methyl]-1,2-oxazol-5-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)N(C)CC(=NO1)C=C1CC(C(O)=O)NC(=O)C1=C(Cl)C=CC=C1Cl JKSDTYRGSMOXQG-UHFFFAOYSA-N 0.000 claims 1
AUPOUPAOUCBBRF-UHFFFAOYSA-N 2-[1-[[2-[3-methoxy-4-[(3-methylpyridin-2-yl)carbamoylamino]phenyl]acetyl]amino]-3-methylbutyl]-3h-benzimidazole-5-carboxylic acid Chemical compound COC1=CC(CC(=O)NC(CC(C)C)C=2NC3=CC(=CC=C3N=2)C(O)=O)=CC=C1NC(=O)NC1=NC=CC=C1C AUPOUPAOUCBBRF-UHFFFAOYSA-N 0.000 claims 1
KCVZGACDDWCUCG-UHFFFAOYSA-N 2-[[3-[[[2-(4-phenylmethoxyphenyl)acetyl]amino]methyl]phenyl]methyl]propanedioic acid Chemical compound OC(=O)C(C(O)=O)CC1=CC=CC(CNC(=O)CC=2C=CC(OCC=3C=CC=CC=3)=CC=2)=C1 KCVZGACDDWCUCG-UHFFFAOYSA-N 0.000 claims 1
KKRBITAWQQPGLG-UHFFFAOYSA-N 2-[[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-methylamino]methyl]-1,3-benzoxazole-6-carboxylic acid Chemical compound COC1=CC(CC(=O)N(C)CC=2OC3=CC(=CC=C3N=2)C(O)=O)=CC=C1NC(=O)NC1=CC=CC=C1C KKRBITAWQQPGLG-UHFFFAOYSA-N 0.000 claims 1
WCNKHXIMZZDJQV-UHFFFAOYSA-N 2-acetamido-3-[2-[[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-methylamino]methyl]-1,3-thiazol-4-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)N(C)CC1=NC(CC(NC(C)=O)C(O)=O)=CS1 WCNKHXIMZZDJQV-UHFFFAOYSA-N 0.000 claims 1
QIPBGDDDOQTWGX-UHFFFAOYSA-N 2-acetamido-3-[2-[[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-methylamino]methyl]-4-methyl-1,3-oxazol-5-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)N(C)CC1=NC(C)=C(CC(NC(C)=O)C(O)=O)O1 QIPBGDDDOQTWGX-UHFFFAOYSA-N 0.000 claims 1
VMNWYSAQEDTVNQ-UHFFFAOYSA-N 2-acetamido-3-[3-[3-methyl-1-[[2-(4-phenylmethoxyphenyl)acetyl]amino]butyl]-1,2-oxazol-5-yl]propanoic acid Chemical compound C1=C(CC(NC(C)=O)C(O)=O)ON=C1C(CC(C)C)NC(=O)CC(C=C1)=CC=C1OCC1=CC=CC=C1 VMNWYSAQEDTVNQ-UHFFFAOYSA-N 0.000 claims 1
ORLQGYVOUNNIHK-UHFFFAOYSA-N 2-acetamido-3-[4-[[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-methylamino]methyl]-5-methylpyrazol-1-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)N(C)CC=1C=NN(CC(NC(C)=O)C(O)=O)C=1C ORLQGYVOUNNIHK-UHFFFAOYSA-N 0.000 claims 1
HESKQBGWBVTYMS-UHFFFAOYSA-N 2-acetamido-3-[5-[1-[2-(4-phenylphenyl)acetyl]pyrrolidin-2-yl]-3,4-dihydropyrazol-2-yl]propanoic acid Chemical compound CC(=O)NC(C(O)=O)CN1CCC(C2N(CCC2)C(=O)CC=2C=CC(=CC=2)C=2C=CC=CC=2)=N1 HESKQBGWBVTYMS-UHFFFAOYSA-N 0.000 claims 1
VSUMRFIWRGVNAY-UHFFFAOYSA-N 2-acetamido-3-[5-[[[2-[3-methoxy-4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]-methylamino]methyl]-1,2-thiazol-3-yl]propanoic acid Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)C)C(OC)=CC=1CC(=O)N(C)CC1=CC(CC(NC(C)=O)C(O)=O)=NS1 VSUMRFIWRGVNAY-UHFFFAOYSA-N 0.000 claims 1
NBGAYCYFNGPNPV-UHFFFAOYSA-N 2-aminooxybenzoic acid Chemical class NOC1=CC=CC=C1C(O)=O NBGAYCYFNGPNPV-UHFFFAOYSA-N 0.000 claims 1
QPMPCOARGKUISP-UHFFFAOYSA-N 2-methyl-3-[2-[1-[2-[4-(2-methylphenoxy)phenyl]acetyl]pyrrolidin-2-yl]-1,3-oxazol-5-yl]propanoic acid Chemical compound O1C(CC(C)C(O)=O)=CN=C1C1N(C(=O)CC=2C=CC(OC=3C(=CC=CC=3)C)=CC=2)CCC1 QPMPCOARGKUISP-UHFFFAOYSA-N 0.000 claims 1
DSRQZBFSUYSGLG-UHFFFAOYSA-N 2-methyl-3-[2-[1-[2-[4-[(2-methylphenyl)methoxy]phenyl]acetyl]pyrrolidin-2-yl]-4,5-dihydro-1,3-oxazol-5-yl]propanoic acid Chemical compound O1C(CC(C)C(O)=O)CN=C1C1N(C(=O)CC=2C=CC(OCC=3C(=CC=CC=3)C)=CC=2)CCC1 DSRQZBFSUYSGLG-UHFFFAOYSA-N 0.000 claims 1
BZOVDCSMISNRGC-UHFFFAOYSA-N 2-methyl-3-[4-[1-[2-[4-(2-methylphenoxy)phenyl]acetyl]pyrrolidin-2-yl]imidazol-1-yl]propanoic acid Chemical compound OC(=O)C(C)CN1C=NC(C2N(CCC2)C(=O)CC=2C=CC(OC=3C(=CC=CC=3)C)=CC=2)=C1 BZOVDCSMISNRGC-UHFFFAOYSA-N 0.000 claims 1
LRIBJVKATQNFKO-UHFFFAOYSA-N 2-methyl-3-[5-[1-[2-[4-(2-methylphenoxy)phenyl]acetyl]pyrrolidin-2-yl]-1,2-oxazol-3-yl]propanoic acid Chemical compound O1N=C(CC(C)C(O)=O)C=C1C1N(C(=O)CC=2C=CC(OC=3C(=CC=CC=3)C)=CC=2)CCC1 LRIBJVKATQNFKO-UHFFFAOYSA-N 0.000 claims 1
VFXMNGGXWWHQJU-UHFFFAOYSA-N 2-methyl-3-[5-[1-[2-[4-(2-methylphenoxy)phenyl]acetyl]pyrrolidin-2-yl]-1h-pyrrol-2-yl]propanoic acid Chemical compound N1C(CC(C)C(O)=O)=CC=C1C1N(C(=O)CC=2C=CC(OC=3C(=CC=CC=3)C)=CC=2)CCC1 VFXMNGGXWWHQJU-UHFFFAOYSA-N 0.000 claims 1
FSBZRPANPMXVPG-UHFFFAOYSA-N 3-[3-(1-benzoylpyrrolidin-2-yl)-1,2-oxazol-5-yl]-2-(prop-2-enoxycarbonylamino)propanoic acid Chemical compound O1C(CC(C(=O)O)NC(=O)OCC=C)=CC(C2N(CCC2)C(=O)C=2C=CC=CC=2)=N1 FSBZRPANPMXVPG-UHFFFAOYSA-N 0.000 claims 1
RKIKEEAOIXKBTL-UHFFFAOYSA-N 3-[3-[1-[2-[4-[(3-methylphenyl)methoxy]phenyl]acetyl]pyrrolidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound CC1=CC=CC(COC=2C=CC(CC(=O)N3C(CCC3)C3=NOC(CCC(O)=O)=C3)=CC=2)=C1 RKIKEEAOIXKBTL-UHFFFAOYSA-N 0.000 claims 1
UAVSKMJWNFJQAY-UHFFFAOYSA-N 3-[3-[1-[2-[4-[(4-methylphenoxy)methyl]phenyl]acetyl]pyrrolidin-2-yl]-1,2-oxazol-5-yl]propanoic acid Chemical compound C1=CC(C)=CC=C1OCC(C=C1)=CC=C1CC(=O)N1C(C2=NOC(CCC(O)=O)=C2)CCC1 UAVSKMJWNFJQAY-UHFFFAOYSA-N 0.000 claims 1
ROPNXRAWAXIOCI-UHFFFAOYSA-N 3-[3-[[(2-phenylacetyl)amino]methyl]phenyl]-2-(propylsulfonylamino)propanoic acid Chemical compound CCCS(=O)(=O)NC(C(O)=O)CC1=CC=CC(CNC(=O)CC=2C=CC=CC=2)=C1 ROPNXRAWAXIOCI-UHFFFAOYSA-N 0.000 claims 1
125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 claims 1
125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 claims 1
VNLBCHKCQIDGEW-UHFFFAOYSA-N C(C1=CC=CC=C1)OC1=CC=C(C=N1)CC(=O)N1C(CCC1)C1=NOC(=C1)CCC(=O)O Chemical compound C(C1=CC=CC=C1)OC1=CC=C(C=N1)CC(=O)N1C(CCC1)C1=NOC(=C1)CCC(=O)O VNLBCHKCQIDGEW-UHFFFAOYSA-N 0.000 claims 1
NPLMTMWBZNNBSZ-UHFFFAOYSA-N COc1cc(CC(=O)N2CCCC2c2cc(CC(NC(C)=O)C(O)=O)on2)ccc1OCc1ccccc1 Chemical compound COc1cc(CC(=O)N2CCCC2c2cc(CC(NC(C)=O)C(O)=O)on2)ccc1OCc1ccccc1 NPLMTMWBZNNBSZ-UHFFFAOYSA-N 0.000 claims 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
229930105110 Cyclosporin A Natural products 0.000 claims 1
108010036949 Cyclosporine Proteins 0.000 claims 1
208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
102000014150 Interferons Human genes 0.000 claims 1
108010050904 Interferons Proteins 0.000 claims 1
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 1
MFLCLMHBOLWTHH-UHFFFAOYSA-N Panial Natural products COc1ccc2C=CC(=O)Oc2c1C(O)C=C(/C)C=O MFLCLMHBOLWTHH-UHFFFAOYSA-N 0.000 claims 1
201000004681 Psoriasis Diseases 0.000 claims 1
GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims 1
230000003178 anti-diabetic effect Effects 0.000 claims 1
230000000340 anti-metabolite Effects 0.000 claims 1
239000000924 antiasthmatic agent Substances 0.000 claims 1
229940100197 antimetabolite Drugs 0.000 claims 1
239000002256 antimetabolite Substances 0.000 claims 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
229940124630 bronchodilator Drugs 0.000 claims 1
239000000168 bronchodilator agent Substances 0.000 claims 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims 1
125000002837 carbocyclic group Chemical group 0.000 claims 1
150000001721 carbon Chemical group 0.000 claims 1
150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 claims 1
229960001265 ciclosporin Drugs 0.000 claims 1
125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
239000003246 corticosteroid Substances 0.000 claims 1
229960001334 corticosteroids Drugs 0.000 claims 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 claims 1
229930182912 cyclosporin Natural products 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
229960002714 fluticasone Drugs 0.000 claims 1
MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 1
125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
125000002632 imidazolidinyl group Chemical group 0.000 claims 1
229960001438 immunostimulant agent Drugs 0.000 claims 1
239000003022 immunostimulating agent Substances 0.000 claims 1
230000003308 immunostimulating effect Effects 0.000 claims 1
229960003444 immunosuppressant agent Drugs 0.000 claims 1
239000003018 immunosuppressive agent Substances 0.000 claims 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
125000001041 indolyl group Chemical group 0.000 claims 1
229940047124 interferons Drugs 0.000 claims 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims 1
125000001786 isothiazolyl group Chemical group 0.000 claims 1
125000004284 isoxazol-3-yl group Chemical group [H]C1=C([H])C(*)=NO1 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
229960000485 methotrexate Drugs 0.000 claims 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
229960001664 mometasone Drugs 0.000 claims 1
QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 1
229960005127 montelukast Drugs 0.000 claims 1
201000006417 multiple sclerosis Diseases 0.000 claims 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
210000000056 organ Anatomy 0.000 claims 1
201000008482 osteoarthritis Diseases 0.000 claims 1
125000001715 oxadiazolyl group Chemical group 0.000 claims 1
125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 claims 1
125000000466 oxiranyl group Chemical group 0.000 claims 1
239000001301 oxygen Substances 0.000 claims 1
229910052760 oxygen Inorganic materials 0.000 claims 1
125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 claims 1
125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 claims 1
125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 claims 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 1
125000004193 piperazinyl group Chemical group 0.000 claims 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
239000000651 prodrug Chemical class 0.000 claims 1
229940002612 prodrug Drugs 0.000 claims 1
125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
125000003373 pyrazinyl group Chemical group 0.000 claims 1
125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 claims 1
125000002755 pyrazolinyl group Chemical group 0.000 claims 1
125000003226 pyrazolyl group Chemical group 0.000 claims 1
125000002098 pyridazinyl group Chemical group 0.000 claims 1
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
229960002052 salbutamol Drugs 0.000 claims 1
229960004017 salmeterol Drugs 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
229920006395 saturated elastomer Polymers 0.000 claims 1
229960002930 sirolimus Drugs 0.000 claims 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
125000001424 substituent group Chemical group 0.000 claims 1
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 1
229960001940 sulfasalazine Drugs 0.000 claims 1
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 1
229960000278 theophylline Drugs 0.000 claims 1
125000001113 thiadiazolyl group Chemical group 0.000 claims 1
125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
238000002054 transplantation Methods 0.000 claims 1
125000004306 triazinyl group Chemical group 0.000 claims 1
125000001425 triazolyl group Chemical group 0.000 claims 1
108010044426 integrins Proteins 0.000 description 16
102000006495 integrins Human genes 0.000 description 16
210000004027 cell Anatomy 0.000 description 11
102000016359 Fibronectins Human genes 0.000 description 10
108010067306 Fibronectins Proteins 0.000 description 10
239000005557 antagonist Substances 0.000 description 9
230000023404 leukocyte cell-cell adhesion Effects 0.000 description 9
101710178046 Chorismate synthase 1 Proteins 0.000 description 7
101710152695 Cysteine synthase 1 Proteins 0.000 description 7
102100032831 Protein ITPRID2 Human genes 0.000 description 7
125000000547 substituted alkyl group Chemical group 0.000 description 7
210000000265 leukocyte Anatomy 0.000 description 6
108090000765 processed proteins & peptides Proteins 0.000 description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
ZNOLGFHPUIJIMJ-UHFFFAOYSA-N fenitrothion Chemical compound COP(=S)(OC)OC1=CC=C([N+]([O-])=O)C(C)=C1 ZNOLGFHPUIJIMJ-UHFFFAOYSA-N 0.000 description 5
108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 4
102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 4
108010016626 Dipeptides Proteins 0.000 description 3
150000001413 amino acids Chemical group 0.000 description 3
230000000694 effects Effects 0.000 description 3
150000002993 phenylalanine derivatives Chemical class 0.000 description 3
125000003107 substituted aryl group Chemical group 0.000 description 3
102000001189 Cyclic Peptides Human genes 0.000 description 2
108010069514 Cyclic Peptides Proteins 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
QCSFMCFHVGTLFF-NHCYSSNCSA-N Leu-Asp-Val Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O QCSFMCFHVGTLFF-NHCYSSNCSA-N 0.000 description 2
102000004264 Osteopontin Human genes 0.000 description 2
108010081689 Osteopontin Proteins 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000007815 allergy Effects 0.000 description 2
125000004104 aryloxy group Chemical group 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
108010083708 leucyl-aspartyl-valine Proteins 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000000816 peptidomimetic Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
230000037390 scarring Effects 0.000 description 2
150000003384 small molecules Chemical class 0.000 description 2
125000003831 tetrazolyl group Chemical group 0.000 description 2
125000004580 4,5-dihydroimidazol-2-yl group Chemical group N1C(=NCC1)* 0.000 description 1
CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
OYNANFOWNSGDJL-UHFFFAOYSA-N 4-sulfanylpyrrolidin-1-ium-2-carboxylate Chemical compound OC(=O)C1CC(S)CN1 OYNANFOWNSGDJL-UHFFFAOYSA-N 0.000 description 1
XUUXCWCKKCZEAW-YFKPBYRVSA-N Arg-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
210000000712 G cell Anatomy 0.000 description 1
101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
102100032818 Integrin alpha-4 Human genes 0.000 description 1
102100025304 Integrin beta-1 Human genes 0.000 description 1
DLCOFDAHNMMQPP-SRVKXCTJSA-N Leu-Asp-Leu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O DLCOFDAHNMMQPP-SRVKXCTJSA-N 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
229910006069 SO3H Inorganic materials 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
206010053648 Vascular occlusion Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
125000004442 acylamino group Chemical group 0.000 description 1
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
230000010085 airway hyperresponsiveness Effects 0.000 description 1
125000004450 alkenylene group Chemical group 0.000 description 1
125000004171 alkoxy aryl group Chemical group 0.000 description 1
125000002947 alkylene group Chemical group 0.000 description 1
150000001409 amidines Chemical class 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
238000010171 animal model Methods 0.000 description 1
206010002906 aortic stenosis Diseases 0.000 description 1
125000005325 aryloxy aryl group Chemical group 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
125000004181 carboxyalkyl group Chemical group 0.000 description 1
125000005026 carboxyaryl group Chemical group 0.000 description 1
125000005352 carboxycycloalkyl group Chemical group 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
208000023819 chronic asthma Diseases 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
230000006378 damage Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000012634 fragment Substances 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
210000000224 granular leucocyte Anatomy 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
125000005553 heteroaryloxy group Chemical group 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
150000002461 imidazolidines Chemical class 0.000 description 1
150000002462 imidazolines Chemical class 0.000 description 1
125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
208000014674 injury Diseases 0.000 description 1
108010024069 integrin alpha9 Proteins 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000000203 mixture Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
230000023578 negative regulation of cell adhesion Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
230000003950 pathogenic mechanism Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
229940083254 peripheral vasodilators imidazoline derivative Drugs 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000032258 transport Effects 0.000 description 1
150000003667 tyrosine derivatives Chemical class 0.000 description 1
208000021331 vascular occlusion disease Diseases 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Neurology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

ZA200205142A 1999-12-28 2002-06-26 Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune and respiratory diseases. ZA200205142B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US17326099P	1999-12-28	1999-12-28

Publications (1)

Publication Number	Publication Date
ZA200205142B true ZA200205142B (en)	2003-09-29

Family

ID=22631221

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200205142A ZA200205142B (en)	1999-12-28	2002-06-26	Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune and respiratory diseases.

Country Status (35)

Country	Link
US (4)	US20020049236A1 (pl)
EP (1)	EP1244656A1 (pl)
JP (1)	JP2003519697A (pl)
KR (1)	KR20020067050A (pl)
CN (1)	CN1413210A (pl)
AP (1)	AP2002002565A0 (pl)
AR (1)	AR029216A1 (pl)
AU (1)	AU2018301A (pl)
BG (1)	BG106867A (pl)
BR (1)	BR0016818A (pl)
CA (1)	CA2396087A1 (pl)
CO (1)	CO5261616A1 (pl)
CR (1)	CR6682A (pl)
CZ (1)	CZ20022072A3 (pl)
EA (1)	EA004673B1 (pl)
EE (1)	EE200200372A (pl)
GT (1)	GT200000226A (pl)
HU (1)	HUP0203897A3 (pl)
IL (1)	IL149758A0 (pl)
IS (1)	IS6382A (pl)
MA (1)	MA26861A1 (pl)
NO (1)	NO20023085D0 (pl)
NZ (1)	NZ518886A (pl)
OA (1)	OA12126A (pl)
PA (1)	PA8509301A1 (pl)
PE (1)	PE20010987A1 (pl)
PL (1)	PL357109A1 (pl)
SK (1)	SK8692002A3 (pl)
SV (1)	SV2002000246A (pl)
TN (1)	TNSN00256A1 (pl)
TR (1)	TR200201668T2 (pl)
UY (1)	UY26512A1 (pl)
WO (1)	WO2001051487A1 (pl)
YU (1)	YU41202A (pl)
ZA (1)	ZA200205142B (pl)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2018301A (en) *	1999-12-28	2001-07-24	Pfizer Products Inc.	Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
US6960597B2 (en) *	2000-06-30	2005-11-01	Orth-Mcneil Pharmaceutical, Inc.	Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
CN100471838C (zh) *	2000-12-28	2009-03-25	第一制药株式会社	Vla-4抑制剂
EP2335700A1 (en)	2001-07-25	2011-06-22	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C virus polymerase inhibitors with a heterobicylic structure
US7273889B2 (en) *	2002-09-25	2007-09-25	Innovative Drug Delivery Systems, Inc.	NMDA receptor antagonist formulation with reduced neurotoxicity
WO2004082638A2 (en) *	2003-03-17	2004-09-30	Syrrx, Inc.	Histone deacetylase inhibitors
MXPA06000850A (es)	2003-07-24	2006-03-30	Daiichi Seiyaku Co	Compuesto de acido ciclohexancarboxilico.
US20050176755A1 (en) *	2003-10-31	2005-08-11	Dyatkin Alexey B.	Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists
BRPI0506676A (pt) *	2004-02-10	2007-05-15	Janssen Phamaceutica N V	piridazinona uréias como antagonistas de integrinas alfa4
EP1720839A1 (en) *	2004-02-10	2006-11-15	Janssen Pharmaceutica N.V.	Pyridazinones as antagonists of a4 integrins
CA2553879C (en)	2004-02-20	2011-02-22	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
TW200610754A (en) *	2004-06-14	2006-04-01	Daiichi Seiyaku Co	Vla-4 inhibitor
US7453002B2 (en) *	2004-06-15	2008-11-18	Bristol-Myers Squibb Company	Five-membered heterocycles useful as serine protease inhibitors
EP1802612A1 (en) *	2004-10-12	2007-07-04	Amgen, Inc	Novel b1 bradykinin receptor antagonists
WO2006133045A1 (en) *	2005-06-03	2006-12-14	Elan Pharma International, Limited	Nanoparticulate benidipine compositions
AU2006254936A1 (en) *	2005-06-07	2006-12-14	The Trustees Of The University Of Pennesylvania	Inhibitors of the alpha2beta1/GPIa-IIa integrin
US8987306B2 (en) *	2005-06-07	2015-03-24	The Trustees Of The University Of Pennsylvania	Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
WO2007069635A1 (ja)	2005-12-13	2007-06-21	Daiichi Sankyo Company, Limited	Ｖｌａ－４阻害薬
PT1984344E (pt) *	2005-12-29	2012-12-21	Lexicon Pharmaceuticals Inc	Derivados de aminoácidos multicíclicos e métodos para a sua utilização
EP2510941A3 (en)	2007-02-20	2013-01-23	Merrimack Pharmaceuticals, Inc.	Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
US8012886B2 (en) *	2007-03-07	2011-09-06	Asm Assembly Materials Ltd	Leadframe treatment for enhancing adhesion of encapsulant thereto
NZ589086A (en)	2008-04-11	2012-09-28	Merrimack Pharmaceuticals Inc	Human serum albumin (HSA) linkers and conjugates thereof
BRPI0921586A2 (pt) *	2008-11-18	2019-09-24	Merrimack Pharmaceuticals Inc	articuladores de albumina de soro humana e conjugados destes
US20120258093A1 (en)	2009-08-20	2012-10-11	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
RS66261B1 (sr)	2010-10-25	2024-12-31	Biogen Ma Inc	Postupci za određivanje razlika u aktivnosti alfa-4 integrina uspostavljanjem korelacije sa razlikama u nivoima svcam i/ili smadcam
JP5971657B2 (ja) *	2011-04-20	2016-08-17	塩野義製薬株式会社	Ｔｒｐｖ４阻害活性を有する芳香族複素環誘導体
JP2014517074A (ja)	2011-06-24	2014-07-17	アムジエン・インコーポレーテツド	Ｔｒｐｍ８アンタゴニストおよび治療におけるそれらの使用
CA2839699A1 (en)	2011-06-24	2012-12-27	Amgen Inc.	Trpm8 antagonists and their use in treatments
CN102268067A (zh) *	2011-06-29	2011-12-07	河北师范大学	一种含ldv序列短肽的聚乙二醇化衍生物
CA2850885A1 (en)	2011-10-17	2013-04-25	Westfaelische Wilhelms-Universitaet Muenster	Assessment of pml risk and methods based thereon
CA2857344C (en)	2011-12-21	2019-02-12	Novira Therapeutics, Inc.	Hepatitis b antiviral agents
US8952009B2 (en)	2012-08-06	2015-02-10	Amgen Inc.	Chroman derivatives as TRPM8 inhibitors
SG11201501362PA (en)	2012-08-28	2015-03-30	Janssen Sciences Ireland Uc	Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
WO2014036520A1 (en)	2012-08-30	2014-03-06	Merrimack Pharmaceuticals, Inc.	Combination therapies comprising anti-erbb3 agents
CA2899706C (en)	2013-02-28	2021-10-19	Janssen Sciences Ireland Uc	Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
WO2014161888A1 (en)	2013-04-03	2014-10-09	Janssen R&D Ireland	N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (ar)	2013-05-17	2020-07-05	Janssen Sciences Ireland Uc	مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
WO2014184365A1 (en)	2013-05-17	2014-11-20	Janssen R&D Ireland	Sulphamoylthiophenamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
EP3357906B1 (en)	2013-07-25	2019-12-04	Janssen Sciences Ireland Unlimited Company	Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9567299B2 (en)	2013-10-23	2017-02-14	Janssen Sciences Ireland Uc	Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10392349B2 (en)	2014-01-16	2019-08-27	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en)	2014-01-16	2015-10-27	Novira Therapeutics, Inc.	Azepane derivatives and methods of treating hepatitis B infections
AU2015214096B2 (en)	2014-02-05	2021-02-11	Novira Therapeutics, Inc.	Combination therapy for treatment of HBV infections
DK3102572T3 (en)	2014-02-06	2019-02-04	Janssen Sciences Ireland Uc	SULFAMOYLPYRROLAMIDE DERIVATIVES AND THEIR USE AS MEDICINES TO TREAT HEPATITIS B
EP3160508B1 (en) *	2014-06-30	2020-08-05	The UAB Research Foundation	Novel rexinoid compounds and methods of using rexinoid compounds for treating metabolic disorders and cancer
WO2016149581A1 (en)	2015-03-19	2016-09-22	Novira Therapeutics, Inc.	Azocane and azonane derivatives and methods of treating hepatitis b infections
US10875876B2 (en)	2015-07-02	2020-12-29	Janssen Sciences Ireland Uc	Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10077239B2 (en)	2015-09-29	2018-09-18	Novira Therapeutics, Inc.	Crystalline forms of a hepatitis B antiviral agent
KR20180129943A (ko)	2016-04-15	2018-12-05	노비라 테라퓨틱스, 인코포레이티드	캡시드 조립 억제제를 포함하는 배합물 및 방법
MA52019A (fr)	2018-03-14	2021-01-20	Janssen Sciences Ireland Unlimited Co	Schéma posologique de modulateur d'assemblage de capside
US20230033021A1 (en)	2018-06-20	2023-02-02	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
TW202045499A (zh)	2019-02-22	2020-12-16	愛爾蘭商健生科學愛爾蘭無限公司	用於治療ｈｂｖ感染或ｈｂｖ誘發疾病之醯胺衍生物
AU2020269897A1 (en)	2019-05-06	2021-10-14	Janssen Sciences Ireland Unlimited Company	Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
US20240301512A1 (en)	2021-01-29	2024-09-12	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5192746A (en)	1990-07-09	1993-03-09	Tanabe Seiyaku Co., Ltd.	Cyclic cell adhesion modulation compounds
AU646966B2 (en)	1991-08-23	1994-03-10	Takeda Chemical Industries Ltd.	2-piperazinone compounds, their production and use
AU693143B2 (en)	1993-12-06	1998-06-25	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
US5936065A (en)	1993-12-06	1999-08-10	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
US5821231A (en)	1993-12-06	1998-10-13	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using same
AU2958195A (en)	1994-06-29	1996-01-25	Texas Biotechnology Corporation	Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
JPH10506608A (ja)	1994-07-11	1998-06-30	アセナニューロサイエンシーズ，インコーポレイテッド	白血球接着のインヒビター
US5811391A (en)	1994-08-25	1998-09-22	Cytel Corporation	Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en)	1994-12-24	1996-01-31	Zeneca Ltd	Chemical compounds
US6306840B1 (en) *	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
IL118325A0 (en) *	1995-05-25	1996-10-31	Pont Merck And Pharmaceutical	Integrin receptor antagonists and pharmaceutical compositions containing them
WO1996040781A1 (en)	1995-06-07	1996-12-19	Tanabe Seiyaku Co., Ltd.	CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
WO1997002289A1 (en)	1995-07-06	1997-01-23	Zeneca Limited	Peptide inhibitors of fibronectine
US6248713B1 (en) *	1995-07-11	2001-06-19	Biogen, Inc.	Cell adhesion inhibitors
GB9613112D0 (en)	1996-06-21	1996-08-28	Zeneca Ltd	Chemical compounds
ES2271971T3 (es) *	1996-07-25	2007-04-16	Biogen Idec Ma Inc.	Inhibidores de la adhesion celular.
DE19647380A1 (de)	1996-11-15	1998-05-20	Hoechst Ag	5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
PL323130A1 (en)	1996-11-15	1998-05-25	Hoechst Ag	Application of heterocyclic compounds in production of a pharmaceutic agent, novel heterocyclic compounds and pharmaceutic agent as such
DE19647381A1 (de)	1996-11-15	1998-05-20	Hoechst Ag	Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
WO1998042656A1 (en)	1997-03-21	1998-10-01	Cytel Corporation	Novel compounds
CA2291778A1 (en)	1997-05-29	1998-12-03	Merck & Co., Inc.	Heterocyclic amide compounds as cell adhesion inhibitors
EP1017382B1 (en)	1997-05-29	2006-03-01	Merck & Co., Inc. (a New Jersey corp.)	Biarylalkanoic acids as cell adhesion inhibitors
JP2002501537A (ja)	1997-05-29	2002-01-15	メルクエンドカンパニーインコーポレーテッド	細胞接着阻害薬としてのスルホンアミド類
WO1998054207A1 (en)	1997-05-30	1998-12-03	Celltech Therapeutics Limited	Anti-inflammatory tyrosine derivatives
US6482849B1 (en)	1997-06-23	2002-11-19	Tanabe Seiyaku Co., Ltd.	Inhibitors of α4β1 mediated cell adhesion
AR016387A1 (es)	1997-07-31	2001-07-04	Athena Neurosciences Inc	Compuestos que inhiben la adhesion de leucocitos intermediada por vla-4, metodo para adherir vla-4 en una muestra biologica, composicion farmaceutica,metodo de tratamiento con dichos compuestos
EP1001972A1 (en)	1997-07-31	2000-05-24	Elan Pharmaceuticals, Inc.	Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
AR016133A1 (es)	1997-07-31	2001-06-20	Wyeth Corp	Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria
AU8823498A (en)	1997-07-31	1999-02-22	American Home Products Corporation	Sulfonylated dipeptide compounds which inhibit leukocyte adhesion mediated by vla-4
CA2291473A1 (en)	1997-07-31	1999-02-11	Elan Pharmaceuticals, Inc.	Benzyl compounds which inhibit leukocyte adhesion mediated by vla-4
KR20010022406A (ko)	1997-07-31	2001-03-15	진 엠. 듀발	Ｖｌａ-4에 의해 매개되는 백혈구 유착을 억제하는디펩타이드 및 관련 화합물
EP1001973A1 (en)	1997-07-31	2000-05-24	Elan Pharmaceuticals, Inc.	Compounds which inhibit leukocyte adhesion mediated by vla-4
CN1265674A (zh)	1997-07-31	2000-09-06	伊兰药品公司	能抑制由vla－4介导的白细胞粘连的4－氨基苯基丙氨酸化合物
YU9600A (sh)	1997-08-22	2002-03-18	F. Hoffmann-La Roche Ag.	Derivati n-alkanoilfenilalanina
ATE260243T1 (de)	1997-08-22	2004-03-15	Hoffmann La Roche	N-aroylphenylalaninderivate
DE19741235A1 (de)	1997-09-18	1999-03-25	Hoechst Marion Roussel De Gmbh	Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de)	1997-09-23	1999-03-25	Hoechst Marion Roussel De Gmbh	Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
WO1999020272A1 (en)	1997-10-21	1999-04-29	Merck & Co., Inc.	Azapeptide acids as cell adhesion inhibitors
JP4555468B2 (ja) *	1997-10-31	2010-09-29	アベンテイス・フアルマ・リミテツド	置換アニリド
GB9723789D0 (en)	1997-11-12	1998-01-07	Zeneca Ltd	Chemical compounds
AU1415099A (en) *	1997-11-18	1999-06-07	Merck & Co., Inc.	4-substituted-4-piperidine carboxamide derivatives
DE19751251A1 (de)	1997-11-19	1999-05-20	Hoechst Marion Roussel De Gmbh	Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
WO1999026923A1 (en)	1997-11-20	1999-06-03	Merck & Co., Inc.	Para-aminomethylaryl carboxamide derivatives
AU1463499A (en)	1997-11-21	1999-06-15	Merck & Co., Inc.	Substituted pyrrole derivatives as cell adhesion inhibitors
DE69824037T2 (de)	1997-11-24	2005-06-02	Merck & Co., Inc.	Beta-alanin-derivate als zell-adhäsions-inhibitoren
US6271252B1 (en)	1997-11-24	2001-08-07	Merck & Co., Inc.	Cyclic amino acid derivatives as cell adhesion inhibitors
CZ20002342A3 (cs) *	1997-12-23	2001-11-14	Aventis Pharma Limited	Substituované ß-alaniny
US6197794B1 (en)	1998-01-08	2001-03-06	Celltech Therapeutics Limited	Phenylalanine derivatives
MY153569A (en)	1998-01-20	2015-02-27	Mitsubishi Tanabe Pharma Corp	Inhibitors of ?4 mediated cell adhesion
ID26665A (id) *	1998-01-23	2001-01-25	Novartis Ag	Antagonis vla-4
US6329372B1 (en)	1998-01-27	2001-12-11	Celltech Therapeutics Limited	Phenylalanine derivatives
US6555562B1 (en)	1998-02-26	2003-04-29	Celltech R&D Limited	Phenylalanine derivatives
GB9805655D0 (en)	1998-03-16	1998-05-13	Celltech Therapeutics Ltd	Chemical compounds
US6521626B1 (en)	1998-03-24	2003-02-18	Celltech R&D Limited	Thiocarboxamide derivatives
EP1079825B1 (en)	1998-04-16	2010-07-21	Encysive Pharmaceuticals, Inc	Compounds that inhibit the binding of integrins to their receptors
AU3716499A (en)	1998-04-21	1999-11-08	Aventis Pharma Limited	Substituted diamines and their use as cell adhesion inhibitors
DE19821483A1 (de)	1998-05-14	1999-11-18	Hoechst Marion Roussel De Gmbh	Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9811159D0 (en)	1998-05-22	1998-07-22	Celltech Therapeutics Ltd	Chemical compounds
UA65623C2 (en)	1998-05-28	2004-04-15	Biogen Inc	Vla-4: omepupa-v inhibitors
GB9811969D0 (en)	1998-06-03	1998-07-29	Celltech Therapeutics Ltd	Chemical compounds
GB9812088D0 (en)	1998-06-05	1998-08-05	Celltech Therapeutics Ltd	Chemical compounds
WO1999064395A1 (en)	1998-06-11	1999-12-16	Merck & Co., Inc.	Heterocyclic amide compounds as cell adhesion inhibitors
TW591026B (en)	1998-06-23	2004-06-11	Upjohn Co	Inhibitors of alpha4beta1 mediated cell adhesion
IL139584A0 (en) *	1998-06-30	2002-02-10	Pfizer Prod Inc	Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
GB9814414D0 (en)	1998-07-03	1998-09-02	Celltech Therapeutics Ltd	Chemical compounds
AU1915399A (en)	1998-07-10	2000-02-01	Cytel Corporation	Cs-1 peptidomimetics, compositions and methods of using the same
GB9916374D0 (en)	1998-07-23	1999-09-15	Zeneca Ltd	Chemical compounds
WO2000005223A2 (en)	1998-07-23	2000-02-03	Astrazeneca Ab	Heterocyclic derivatives and their use as integrin inhibitors
PT1114028E (pt)	1998-08-26	2007-02-28	Aventis Pharma Ltd	Aza-biciclos moduladores da inibição da adesão celular
GB9821061D0 (en)	1998-09-28	1998-11-18	Celltech Therapeutics Ltd	Chemical compounds
GB9821222D0 (en)	1998-09-30	1998-11-25	Celltech Therapeutics Ltd	Chemical compounds
GB9821406D0 (en)	1998-10-01	1998-11-25	Celltech Therapeutics Ltd	Chemical compounds
GB9826174D0 (en)	1998-11-30	1999-01-20	Celltech Therapeutics Ltd	Chemical compounds
CA2351464A1 (en)	1998-12-14	2000-06-22	Joan E. Sabalski	3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by vla-4
GB9828074D0 (en)	1998-12-18	1999-02-17	Glaxo Group Ltd	Therapeutically useful compounds
AU2623900A (en)	1999-01-22	2000-08-07	American Home Products Corporation	Compounds which inhibit leukocyte adhesion mediated by vla-4
CN1231212C (zh)	1999-01-22	2005-12-14	依兰制药公司	抑制vla－4介导的白细胞粘着的多环化合物
TW593284B (en)	1999-01-22	2004-06-21	Elan Pharm Inc	Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
AU2018301A (en) *	1999-12-28	2001-07-24	Pfizer Products Inc.	Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases

2000
- 2000-12-15 AU AU20183/01A patent/AU2018301A/en not_active Abandoned
- 2000-12-15 OA OA1200200193A patent/OA12126A/en unknown
- 2000-12-15 NZ NZ518886A patent/NZ518886A/en unknown
- 2000-12-15 HU HU0203897A patent/HUP0203897A3/hu unknown
- 2000-12-15 KR KR1020027008400A patent/KR20020067050A/ko not_active Application Discontinuation
- 2000-12-15 EP EP00983429A patent/EP1244656A1/en not_active Withdrawn
- 2000-12-15 EE EEP200200372A patent/EE200200372A/xx unknown
- 2000-12-15 EA EA200200619A patent/EA004673B1/ru not_active IP Right Cessation
- 2000-12-15 JP JP2001551869A patent/JP2003519697A/ja not_active Withdrawn
- 2000-12-15 AP APAP/P/2002/002565A patent/AP2002002565A0/en unknown
- 2000-12-15 BR BR0016818-1A patent/BR0016818A/pt not_active IP Right Cessation
- 2000-12-15 WO PCT/IB2000/001893 patent/WO2001051487A1/en not_active Application Discontinuation
- 2000-12-15 SK SK869-2002A patent/SK8692002A3/sk not_active Application Discontinuation
- 2000-12-15 CZ CZ20022072A patent/CZ20022072A3/cs unknown
- 2000-12-15 IL IL14975800A patent/IL149758A0/xx unknown
- 2000-12-15 PL PL00357109A patent/PL357109A1/pl not_active Application Discontinuation
- 2000-12-15 CN CN00817813A patent/CN1413210A/zh active Pending
- 2000-12-15 CA CA002396087A patent/CA2396087A1/en not_active Abandoned
- 2000-12-15 TR TR2002/01668T patent/TR200201668T2/xx unknown
- 2000-12-15 YU YU41202A patent/YU41202A/sh unknown
- 2000-12-21 US US09/747,246 patent/US20020049236A1/en not_active Abandoned
- 2000-12-22 SV SV2000000246A patent/SV2002000246A/es unknown
- 2000-12-26 TN TNTNSN00256A patent/TNSN00256A1/fr unknown
- 2000-12-27 CO CO00097880A patent/CO5261616A1/es unknown
- 2000-12-27 AR ARP000106961A patent/AR029216A1/es not_active Application Discontinuation
- 2000-12-27 GT GT200000226A patent/GT200000226A/es unknown
- 2000-12-28 PE PE2000001411A patent/PE20010987A1/es not_active Application Discontinuation
- 2000-12-28 UY UY26512A patent/UY26512A1/es not_active Application Discontinuation
- 2000-12-28 PA PA20008509301A patent/PA8509301A1/es unknown
2002
- 2002-05-14 IS IS6382A patent/IS6382A/is unknown
- 2002-06-12 US US10/171,286 patent/US6667331B2/en not_active Expired - Fee Related
- 2002-06-12 US US10/170,289 patent/US6668527B2/en not_active Expired - Fee Related
- 2002-06-14 CR CR6682A patent/CR6682A/es not_active Application Discontinuation
- 2002-06-24 MA MA26709A patent/MA26861A1/fr unknown
- 2002-06-24 BG BG106867A patent/BG106867A/xx unknown
- 2002-06-26 NO NO20023085A patent/NO20023085D0/no not_active Application Discontinuation
- 2002-06-26 ZA ZA200205142A patent/ZA200205142B/en unknown
2003
- 2003-11-05 US US10/702,539 patent/US6903128B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2001051487A1 (en)	2001-07-19
CN1413210A (zh)	2003-04-23
BG106867A (en)	2003-02-28
NO20023085L (no)	2002-06-26
US20030100585A1 (en)	2003-05-29
AU2018301A (en)	2001-07-24
EE200200372A (et)	2003-12-15
HUP0203897A2 (hu)	2003-03-28
TNSN00256A1 (fr)	2002-05-30
US20020049236A1 (en)	2002-04-25
IL149758A0 (en)	2002-11-10
US6903128B2 (en)	2005-06-07
EP1244656A1 (en)	2002-10-02
CA2396087A1 (en)	2001-07-19
IS6382A (is)	2002-05-14
US6667331B2 (en)	2003-12-23
KR20020067050A (ko)	2002-08-21
TR200201668T2 (tr)	2002-11-21
US20030004196A1 (en)	2003-01-02
SK8692002A3 (en)	2003-06-03
PA8509301A1 (es)	2002-12-11
HUP0203897A3 (en)	2005-06-28
OA12126A (en)	2006-05-05
PE20010987A1 (es)	2001-10-02
US20040102496A1 (en)	2004-05-27
CZ20022072A3 (cs)	2003-05-14
EA200200619A1 (ru)	2002-10-31
PL357109A1 (pl)	2004-07-12
US6668527B2 (en)	2003-12-30
MA26861A1 (fr)	2004-12-20
YU41202A (sh)	2005-03-15
SV2002000246A (es)	2002-07-16
AR029216A1 (es)	2003-06-18
GT200000226A (es)	2002-06-20
BR0016818A (pt)	2002-10-01
EA004673B1 (ru)	2004-06-24
NO20023085D0 (no)	2002-06-26
AP2002002565A0 (en)	2002-06-30
JP2003519697A (ja)	2003-06-24
UY26512A1 (es)	2001-07-31
CR6682A (es)	2004-01-14
CO5261616A1 (es)	2003-03-31
NZ518886A (en)	2004-02-27

Publication	Publication Date	Title
ZA200205142B (en)	2003-09-29	Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune and respiratory diseases.
JP3676677B2 (ja)	2005-07-27	炎症性疾患、自己免疫疾患および呼吸疾患の治療において有用なｖｌａ−４依存性細胞結合の非ペプチジル阻害薬
CA2988147C (en)	2023-06-13	4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
AU2008205143A1 (en)	2008-07-17	Thiophene carboxamides as Factor Xa inhibitors
JP2004511434A (ja)	2004-04-15	インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
JP2001520643A (ja)	2001-10-30	エンドテリン介在障害治療用のスルホンアミド類
CA2549242A1 (en)	2005-06-16	Hydroxamic acid esters and pharmaceutical use thereof
EP2094272B1 (en)	2014-03-26	Nitrogen containing substituted heterocycles as platelet adp receptor inhibitors
CN101228158A (zh)	2008-07-23	作为ccr1拮抗剂的8-氮杂双环[3.2.1]辛-3-基的n-酰胺衍生物
JP2003500339A (ja)	2003-01-07	インテグリン受容体アンタゴニスト
JP2003511356A (ja)	2003-03-25	併用療法のためのサイトカイン媒介性シグナル伝達経路のモジュレーター及びインテグリンαｖβ３受容体アンタゴニスト
MXPA02006599A (en)	2003-02-07	Nonpeptidyl inhibitors of vla4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
MXPA00012625A (en)	2001-07-31	Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
DE19948269A1 (de)	2001-04-12	Neue Integrinrezeptorantagonisten
MXPA00005155A (en)	2001-07-03	1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS&agr;v